Price movement over the last 24 hours
Alcon AG vs Badger Meter Inc — how do they compare? Alcon AG trades at $66.96 (market cap $32.69B), while Badger Meter Inc trades at $146.51 (market cap $4.37B). The key difference: Alcon AG is far larger — about 7.5× Badger Meter Inc's market cap, and Badger Meter Inc pays the higher dividend (1.07%). Which is the better fit depends on your goals.
| ALC | BMI | |
|---|---|---|
Market Cap | $32.69B | $4.37B |
Sector | Health | Technology |
52-Week High | $92.22 | $245.81 |
52-Week Low | $62.02 | $113.41 |
Enterprise Value | $36.28B | $4.17B |
Dividend Yield | 0.54% | 1.07% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Badger Meter (BMI) trades at $149.79, up 2.69% with a bullish technical signal from moving averages. The company maintains strong profitability with 14.56% net income margin and 19.6% ROE, though recent earnings misses and a securities class action lawsuit create headwinds. Valuation metrics show a P/E of 33.89 and P/S of 4.93, above industry averages.
While BMI demonstrates solid fundamentals and technical strength, the stock faces significant legal risks from multiple class action lawsuits alleging securities fraud. Analyst consensus is mixed with 28% buy ratings but a $144.80 price target below current levels. The combination of legal overhang and premium valuation creates a cautious near-term outlook despite strong operational performance.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Badger Meter provides industry-leading water management solutions. Its smart measurement hardware and software analytics help water utilities and industrial customers optimize operations and conserve natural resources.
Read more on BMI →